Hyperlipidemia Drugs Market Trends, Scope, Size, Growth And Analysis 2022-27

hyperlipidemia drugs market

According to the latest report by IMARC Group “Hyperlipidemia Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027“, The global hyperlipidemia drugs market reached a value of US$ 21.7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 24.8 Billion by 2027, exhibiting a CAGR of 2.17% during 2022-2027.

Hyperlipidemia refers to a condition that causes abnormally high levels of fats or lipids in the blood. It is a common type of dyslipidemia that can be inherited or result from an unhealthy lifestyle and poor diet. The disorder may lead to cardiac stroke, peripheral vascular diseases, obesity, hypertension, and cardiovascular disorders(CVDs). Hyperlipidemia can be detected by performing a blood test called a lipid panel or lipid profile. Statins are the primary line of treatment in secondary hyperlipidemia caused by an unhealthy lifestyle. Some of the other common drugs used in the treatment of hyperlipidemia are bile acid sequestrants, PCSK9, and miscellaneous antihyperlipidemic agents, which help reduce the production of cholesterol in the liver. They also lower the number of lipids in the bloodstream and reduce inflammation and damage done to the cells.

Request for a free sample copy of this report: https://www.imarcgroup.com/hyperlipidemia-drugs-market/requestsample

Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Market Trends:

The global hyperlipidemia drugs market is primarily driven by the increasing awareness regarding the associated risks of CVDs and high cholesterol. Governments are introducing new guidelines redefining at-risk patient groups and recommending the use of anti-hyperlipidemic to lower the risk of these diseases. In addition to this, the upcoming patent expiration has resulted in the genericization of statin and cholesterol absorption inhibitors, which is significantly augmenting the market growth. Furthermore, the launch of innovative products, such as the development of novel drugs, which offer improved efficacy and safety profile, is positively impacting the market across the globe. Moreover, there has been extensive research and development (R&D) activities for developing innovative drugs. On account of these factors, the market is expected to exhibit a CAGR of 2% during the forecast period (2021-2026).

Breakup by Drug Type:

  • Statins
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • PCSK9 Inhibitors
  • Others

Breakup by End User:

  • Hospitals
  • Clinics
  • Others

Market Breakup by Region:

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

Competitive Landscape with Key Player:

  • Amgen Inc.
  • AstraZeneca PLC
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • Esperion Therapeutics Inc.
  • GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc)
  • Immuron Limited
  • Ionis Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi S.A.

Ask Analyst for Customization and Browse full report with TOC & List of Figure: https://www.imarcgroup.com/hyperlipidemia-drugs-market

As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

If you want latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

Happy Reading!!!!

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top